UY34054A - FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 - Google Patents
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7Info
- Publication number
- UY34054A UY34054A UY0001034054A UY34054A UY34054A UY 34054 A UY34054 A UY 34054A UY 0001034054 A UY0001034054 A UY 0001034054A UY 34054 A UY34054 A UY 34054A UY 34054 A UY34054 A UY 34054A
- Authority
- UY
- Uruguay
- Prior art keywords
- antibody
- beta
- alpha
- formulations
- formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481522P | 2011-05-02 | 2011-05-02 | |
| US201161544054P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34054A true UY34054A (es) | 2012-11-30 |
Family
ID=46147702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034054A UY34054A (es) | 2011-05-02 | 2012-05-02 | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
Country Status (39)
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| KR20140047628A (ko) | 2011-07-06 | 2014-04-22 | 네스텍 소시에테아노님 | Ｔｎｆ알파로의 생물학적 치료요법에 대한 중화 자가항체의 검출을 위한 검정 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9764093B2 (en) * | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
| AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| RS63856B1 (sr) * | 2013-07-05 | 2023-01-31 | Stellar Biome Inc | Probiotički sojevi bakterija za prevenciju i lečenje bolesti u usnoj duplji |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| WO2015080513A1 (en) * | 2013-11-29 | 2015-06-04 | Hanwha Chemical Corporation | A liquid formulation of a fusion protein comprising tnfr and fc region |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| WO2016057424A1 (en) | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| ES2988823T3 (es) * | 2014-12-03 | 2024-11-21 | Csl Behring Ag | Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas |
| CN107250798A (zh) | 2014-12-05 | 2017-10-13 | 雀巢产品技术援助有限公司 | 用于检测患者样品中的生物制品的间接均相迁移率变动试验 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN115400220A (zh) * | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
| AU2017234010B2 (en) | 2016-03-14 | 2024-06-13 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| CA3017743A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| US10918716B2 (en) | 2016-05-04 | 2021-02-16 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating Crohn's disease |
| EP3468597A1 (en) * | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
| AU2018256840A1 (en) | 2017-04-28 | 2019-11-07 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) |
| KR20200037863A (ko) * | 2017-08-25 | 2020-04-09 | 오메로스 코포레이션 | 고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법 |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2019198100A1 (en) | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Antibody formulation |
| US12433947B2 (en) | 2018-04-10 | 2025-10-07 | Dr. Reddy's Laboratories Limited | Stable formulations of therapeutic antibody |
| EP3843783A1 (en) * | 2018-08-29 | 2021-07-07 | GlaxoSmithKline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
| CN113874009A (zh) * | 2019-01-08 | 2021-12-31 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病况的方法 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP7778567B2 (ja) * | 2019-04-17 | 2025-12-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| EP3980119A4 (en) * | 2019-06-10 | 2023-06-07 | Takeda Pharmaceutical Company Limited | METHODS FOR PURIFYING ANTIBODIES AND ASSOCIATED COMPOSITIONS |
| WO2021070203A1 (en) * | 2019-10-11 | 2021-04-15 | Dr. Reddy's Laboratories Limited | Stable formulation of integrin antibody |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN115515984B (zh) * | 2020-05-08 | 2026-02-06 | 亘利生物科技(上海)有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| UY39327A (es) * | 2020-07-16 | 2022-02-25 | Abbvie Inc | Anticuerpos anti- alpha-4-beta-7 |
| IL300133A (en) * | 2020-07-31 | 2023-03-01 | Genentech Inc | Anti-integrin antibody compositions in cell 7 and devices |
| EP4243859A4 (en) * | 2020-11-12 | 2024-10-16 | Dr. Reddy's Laboratories Ltd. | STABLE AQUEOUS FORMULATION WITH HIGH CONCENTRATION OF ANTI-INTEGRIN ANTIBODY |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| EP4717712A2 (en) | 2021-12-27 | 2026-04-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| WO2023230620A1 (en) * | 2022-05-27 | 2023-11-30 | Sonnet BioTherapeutics, Inc. | Il-12-albumin-binding domain fusion protein formulations and methods of use thereof |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025041000A1 (en) * | 2023-08-21 | 2025-02-27 | Intas Pharmaceuticals Ltd. | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025149974A1 (en) | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| WO2025177214A1 (en) | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
| WO2025177055A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Combination therapy for treating inflammatory bowel disease |
| WO2026022216A1 (en) * | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| EP0303463B1 (en) | 1987-08-11 | 1994-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Method to control leukocyte extravasation |
| US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| WO1990007321A2 (en) | 1988-12-23 | 1990-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte receptor homing sequences and their uses |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL95501A (en) | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2082160C (en) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| JPH07506566A (ja) | 1992-02-12 | 1995-07-20 | バイオゲン インコーポレイテッド | 炎症性胃腸病の処置 |
| WO1993023526A1 (en) | 1992-05-21 | 1993-11-25 | Center For Blood Research, Inc. | A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON |
| WO1994012214A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
| AU5675794A (en) | 1992-12-15 | 1994-07-04 | Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
| ATE161730T1 (de) | 1993-02-09 | 1998-01-15 | Biogen Inc | Antikörper zur behandlung von insulinabhängigen diabetes |
| US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
| JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| HU220799B1 (hu) | 1994-01-25 | 2002-05-28 | Elan Pharmaceuticals, Inc. | Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen |
| US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6189195B1 (en) | 1995-08-22 | 2001-02-20 | Medrad, Inc. | Manufacture of prefilled syringes |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| CA2817619A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| DK1485127T3 (da) | 2002-02-25 | 2011-10-03 | Elan Pharm Inc | Anvendelse af midler til behandling af inflammation |
| NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| KR100874292B1 (ko) | 2002-11-18 | 2008-12-18 | 케모센트릭스 | 아릴 술폰아마이드 |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| US6886838B1 (en) | 2003-01-22 | 2005-05-03 | Zimmco | Easy dumping cart |
| KR101235507B1 (ko) | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101132820B (zh) | 2005-01-24 | 2010-05-19 | 安塔雷斯制药公司 | 预充式针辅助喷射注入器 |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| EP1948691A1 (en) * | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| AR060487A1 (es) | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
| CL2007003583A1 (es) * | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| EP2205145A4 (en) | 2007-07-06 | 2013-06-19 | Stereotaxis Inc | MANAGEMENT OF A MEDICAL LIVE REMOTE DISPLAY |
| EP2220115A2 (en) * | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| AU2009210741A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| AR073459A1 (es) * | 2008-07-18 | 2010-11-10 | Domantis Ltd | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso |
| NZ592095A (en) * | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| JP2013525260A (ja) * | 2009-04-17 | 2013-06-20 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 急性骨髄性白血病を治療するための組成物および方法 |
| CN101533504A (zh) * | 2009-04-27 | 2009-09-16 | 刘文祥 | 电子医务系统及其装置 |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| US10918716B2 (en) | 2016-05-04 | 2021-02-16 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating Crohn's disease |
-
2012
- 2012-05-02 MX MX2017007134A patent/MX367097B/es unknown
- 2012-05-02 KR KR1020257019939A patent/KR20250093426A/ko active Pending
- 2012-05-02 FI FIEP17180247.3T patent/FI3311834T3/fi active
- 2012-05-02 DK DK12722973.0T patent/DK2704742T3/en active
- 2012-05-02 KR KR1020237002891A patent/KR20230021758A/ko not_active Ceased
- 2012-05-02 KR KR1020207020503A patent/KR102308938B1/ko active Active
- 2012-05-02 TW TW109140548A patent/TWI799757B/zh active
- 2012-05-02 IL IL274846A patent/IL274846B2/en unknown
- 2012-05-02 KR KR1020197024347A patent/KR102136208B1/ko active Active
- 2012-05-02 CN CN201280021789.8A patent/CN103533959B/zh active Active
- 2012-05-02 LT LTEP24167554.5T patent/LT4403579T/lt unknown
- 2012-05-02 FI FIEP24167554.5T patent/FI4403579T3/fi active
- 2012-05-02 KR KR1020217031194A patent/KR102493433B1/ko active Active
- 2012-05-02 EP EP24167547.9A patent/EP4378959A3/en active Pending
- 2012-05-02 HR HRP20171457TT patent/HRP20171457T1/hr unknown
- 2012-05-02 SI SI201232102T patent/SI4403579T1/sl unknown
- 2012-05-02 SI SI201231076T patent/SI2704742T1/sl unknown
- 2012-05-02 EP EP24167555.2A patent/EP4438625A3/en active Pending
- 2012-05-02 EP EP17180247.3A patent/EP3311834B1/en active Active
- 2012-05-02 PT PT241675545T patent/PT4403579T/pt unknown
- 2012-05-02 US US14/114,835 patent/US10040855B2/en active Active
- 2012-05-02 DK DK24167554.5T patent/DK4403579T3/da active
- 2012-05-02 AR ARP120101540A patent/AR086238A1/es not_active Application Discontinuation
- 2012-05-02 PL PL12722973T patent/PL2704742T3/pl unknown
- 2012-05-02 PH PH1/2013/502237A patent/PH12013502237A1/en unknown
- 2012-05-02 CN CN201810453958.4A patent/CN108969469A/zh active Pending
- 2012-05-02 MX MX2013012725A patent/MX354101B/es active IP Right Grant
- 2012-05-02 GE GEAP201813302A patent/GEAP201813302A/en unknown
- 2012-05-02 PH PH1/2018/502221A patent/PH12018502221B1/en unknown
- 2012-05-02 IL IL305583A patent/IL305583B2/en unknown
- 2012-05-02 RS RS20171015A patent/RS56429B1/sr unknown
- 2012-05-02 KR KR1020177012979A patent/KR101884406B1/ko active Active
- 2012-05-02 CN CN201810453956.5A patent/CN108969761A/zh active Pending
- 2012-05-02 RS RS20260037A patent/RS67634B1/sr unknown
- 2012-05-02 EA EA201391613A patent/EA032625B1/ru not_active IP Right Cessation
- 2012-05-02 HU HUE12722973A patent/HUE036664T2/hu unknown
- 2012-05-02 TW TW106123969A patent/TWI698254B/zh active
- 2012-05-02 ME MEP-2017-227A patent/ME02858B/me unknown
- 2012-05-02 AU AU2012250872A patent/AU2012250872B2/en active Active
- 2012-05-02 PL PL24167554.5T patent/PL4403579T3/pl unknown
- 2012-05-02 HR HRP20260026TT patent/HRP20260026T1/hr unknown
- 2012-05-02 TW TW108104506A patent/TWI723339B/zh active
- 2012-05-02 MX MX2019009244A patent/MX384203B/es unknown
- 2012-05-02 MY MYPI2013003974A patent/MY188820A/en unknown
- 2012-05-02 CA CA3051418A patent/CA3051418C/en active Active
- 2012-05-02 KR KR1020187018702A patent/KR102014512B1/ko active Active
- 2012-05-02 DK DK17180247.3T patent/DK3311834T3/da active
- 2012-05-02 CN CN201711133991.0A patent/CN107998388B/zh active Active
- 2012-05-02 GE GEAP201213302A patent/GEP20186866B/en unknown
- 2012-05-02 LT LTEP12722973.0T patent/LT2704742T/lt unknown
- 2012-05-02 SM SM20260024T patent/SMT202600024T1/it unknown
- 2012-05-02 TW TW113101357A patent/TWI907924B/zh active
- 2012-05-02 TW TW111148303A patent/TWI832619B/zh active
- 2012-05-02 ES ES12722973.0T patent/ES2646717T3/es active Active
- 2012-05-02 JP JP2014509377A patent/JP6190359B2/ja active Active
- 2012-05-02 SG SG2013080940A patent/SG194730A1/en unknown
- 2012-05-02 EP EP24167554.5A patent/EP4403579B1/en active Active
- 2012-05-02 WO PCT/US2012/036069 patent/WO2012151247A2/en not_active Ceased
- 2012-05-02 KR KR1020137031205A patent/KR101875155B1/ko active Active
- 2012-05-02 CA CA2834900A patent/CA2834900C/en active Active
- 2012-05-02 PE PE2013002433A patent/PE20141672A1/es active IP Right Grant
- 2012-05-02 UY UY0001034054A patent/UY34054A/es not_active Application Discontinuation
- 2012-05-02 EP EP12722973.0A patent/EP2704742B1/en not_active Revoked
- 2012-05-02 TW TW101115710A patent/TWI638661B/zh active
- 2012-05-02 SM SM20170515T patent/SMT201700515T1/it unknown
- 2012-05-02 PT PT127229730T patent/PT2704742T/pt unknown
-
2013
- 2013-10-29 DO DO2013000252A patent/DOP2013000252A/es unknown
- 2013-10-29 CR CR20130556A patent/CR20130556A/es unknown
- 2013-10-30 CL CL2013003145A patent/CL2013003145A1/es unknown
- 2013-10-31 IL IL229169A patent/IL229169B/en active IP Right Grant
- 2013-10-31 MX MX2021008112A patent/MX2021008112A/es unknown
- 2013-10-31 ZA ZA2013/08168A patent/ZA201308168B/en unknown
- 2013-11-01 CO CO13259852A patent/CO6801648A2/es unknown
-
2017
- 2017-04-05 CL CL2017000829A patent/CL2017000829A1/es unknown
- 2017-05-10 JP JP2017094129A patent/JP6467457B2/ja active Active
- 2017-06-21 AU AU2017204192A patent/AU2017204192B2/en active Active
- 2017-10-11 CY CY20171101057T patent/CY1119436T1/el unknown
- 2017-10-27 ZA ZA2017/07310A patent/ZA201707310B/en unknown
-
2018
- 2018-05-18 US US15/983,791 patent/US20180327497A1/en not_active Abandoned
- 2018-06-15 US US16/009,865 patent/US20180346578A1/en not_active Abandoned
- 2018-10-12 HK HK18113059.1A patent/HK1253911A1/en unknown
-
2019
- 2019-01-11 JP JP2019003265A patent/JP6751450B2/ja active Active
- 2019-07-17 PH PH12019501662A patent/PH12019501662A1/en unknown
- 2019-08-15 AU AU2019216679A patent/AU2019216679B2/en active Active
-
2020
- 2020-01-26 IL IL272237A patent/IL272237B/en unknown
- 2020-02-11 US US16/787,521 patent/US11560434B2/en active Active
- 2020-06-12 CL CL2020001579A patent/CL2020001579A1/es unknown
- 2020-08-14 JP JP2020136927A patent/JP7107997B2/ja active Active
-
2021
- 2021-04-23 US US17/239,512 patent/US12286479B2/en active Active
- 2021-08-31 AU AU2021225160A patent/AU2021225160B2/en active Active
-
2022
- 2022-02-23 IL IL290848A patent/IL290848A/en unknown
- 2022-02-23 IL IL290849A patent/IL290849A/en unknown
- 2022-06-10 EC ECSENADI202246340A patent/ECSP22046340A/es unknown
- 2022-07-14 JP JP2022112814A patent/JP7636651B2/ja active Active
- 2022-10-13 US US18/046,450 patent/US20230312727A1/en active Pending
-
2023
- 2023-12-04 AU AU2023274233A patent/AU2023274233A1/en active Pending
-
2024
- 2024-10-11 US US18/912,587 patent/US20250034263A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005609A patent/JP2025061332A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34054A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 | |
| UY34053A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 | |
| BR112014018879A8 (pt) | Composto e composição farmacêutica e combinação compreendendo dito composto | |
| BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
| BR112014003640A8 (pt) | métodos para perda de peso e composições cetogênicas | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| BR112017008033A2 (pt) | composição farmacêutica para administração oral e respectivo processo de preparação | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| BR112013027369A2 (pt) | composições e métodos | |
| AR093717A1 (es) | Composiciones y metodos para el tratamiento de la caries dental | |
| BR112013025610A2 (pt) | uso de um metapneumovírus aviário vivo, e, composição farmacêutica | |
| TN2013000455A1 (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
| ECSP13013059A (es) | Formulación para anticuerpo anti- 4 7 | |
| CR20120465A (es) | Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20201019 |